See more : Apple Inc. (APC.F) Income Statement Analysis – Financial Results
Complete financial analysis of Sana Biotechnology, Inc. (SANA) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Sana Biotechnology, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Dynagreen Environmental Protection Group Co., Ltd. (1330.HK) Income Statement Analysis – Financial Results
- Five9, Inc. (0TMV.L) Income Statement Analysis – Financial Results
- FDK Corporation (6955.T) Income Statement Analysis – Financial Results
- Logistics Innovation Technologies Corp. (LITTW) Income Statement Analysis – Financial Results
- Crest Resources Inc. (CRES.CN) Income Statement Analysis – Financial Results
Sana Biotechnology, Inc. (SANA)
About Sana Biotechnology, Inc.
Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. The company develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, cardiovascular diseases, genetic disorders, and others. Its product candidates include SG295 and SG242 that target CD19+ cancer cells, including non-Hodgkin Lymphoma, chronic lymphocytic leukemia, and acute lymphoblastic leukemia; SG221 and SG239 for the treatment of multiple myeloma; and SG328 for ornithine transcarbamylase deficiency. It also develops SG418 for sickle cell disease and beta-thalassemia; SC291, a CD19 allogeneic T cell therapy; SC255 for multiple myeloma; SC451 for type I diabetes mellitus; and SC379 for secondary progressive multiple sclerosis, Pelizaeus-Merzbacher disease, and Huntington's disease. Sana Biotechnology, Inc. was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. The company was incorporated in 2018 and is headquartered in Seattle, Washington.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 30.87M | 27.73M | 17.91M | 10.17M | 3.92M | 1.00K |
| Gross Profit | -30.87M | -27.73M | -17.91M | -10.17M | -3.92M | -1.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 221.64M | 201.00M | 306.50M | 257.88M | 119.38M | 4.01M |
| General & Administrative | 73.30M | 71.56M | 50.41M | 28.27M | 21.78M | 8.41M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -4.21M |
| SG&A | 73.30M | 71.56M | 50.41M | 28.27M | 21.78M | 4.21M |
| Other Expenses | 0.00 | -674.00K | 305.00K | 97.00K | -29.00K | 0.00 |
| Operating Expenses | 294.94M | 272.56M | 356.91M | 286.15M | 141.15M | 8.22M |
| Cost & Expenses | 325.81M | 272.56M | 356.91M | 286.15M | 141.15M | 8.22M |
| Interest Income | 9.94M | 3.76M | 676.00K | 747.00K | 2.86M | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 30.87M | 27.73M | 17.91M | 10.17M | 3.92M | 1.00K |
| EBITDA | -252.39M | -256.94M | -356.91M | -287.03M | -138.90M | -13.25M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -326.90M | -272.56M | -356.91M | -286.15M | -141.15M | -8.22M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 43.65M | 3.09M | 981.00K | 844.00K | 2.83M | -5.03M |
| Income Before Tax | -283.26M | -269.48M | -355.93M | -285.31M | -138.33M | -13.25M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | -3.09M | -11.75M | -6.67M | -7.55M | 0.00 |
| Net Income | -283.26M | -266.39M | -344.18M | -278.64M | -130.78M | -13.25M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -1.46 | -1.41 | -2.07 | -1.49 | -0.70 | -0.07 |
| EPS Diluted | -1.46 | -1.41 | -2.07 | -1.49 | -0.70 | -0.07 |
| Weighted Avg Shares Out | 194.54M | 188.34M | 166.43M | 187.51M | 187.34M | 187.34M |
| Weighted Avg Shares Out (Dil) | 194.54M | 188.34M | 166.43M | 187.51M | 187.34M | 187.34M |
Sana Biotechnology Publishes Early Clinical Data Showing that SC291, a CD19-directed Allogeneic CAR T Therapy, Evades Immune Detection in Presence of Intact Immune System
Sana Biotechnology to Present at November and December 2023 Investor Conferences
Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes
Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates
Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting
Sana Biotechnology will lay off 29% of workforce
Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M
Sana Biotechnology to Present at September 2023 Investor Conferences
Invaio achieves first registration for citrus greening solution featuring Trecise™ technology
Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates
Source: https://incomestatements.info
Category: Stock Reports